#because fluoroquinolones increase the risk of dissection

[nerdgirlnarrates]

Now the fluoroquinolones go toe to toe! Both of these medications work by binding the topoisomerase IV/gyrase-DNA complex. Their most unique adverse effect is tendon rupture (avoid in kids and older adults!), and they shouldn't be used in myasthenia gravis patients as they can exacerbate the condition. Both can be used as post-exposure prophylaxis for anthrax. So which fluoroquinolone should move forward?

Ciprofloxacin: Of the fluoroquinolones, cipro has the best activity against both pseudomonas and gram negatives, notably the Enterobacteriaceae. It has a wide variety of uses, and among the most interesting (to me) are treatment of the plague and typhoid fever. On the more mundane side, it's mostly used for GI and GU infections. It can also be formulated as ophthalmic or otic drops for corneal ulcers/conjunctivitis and acute otitis externa, respectively. Beware though: it inhibits cytochrome P450, increasing the risk of drug interactions.

Levofloxacin: levo is considered a respiratory fluoroquinolone since it is mostly (but not exclusively) used for respiratory infections. While levo doesn't cover those fascinating bugs of plague and typhoid fever, it makes up for it by not inhibiting cytochrome P450. As with all fluoroquinolones, it should not be taken with dairy, as it can bind to the calcium and be rendered ineffective.

Vote for the best antibiotic

[vicky8588]

Marfan Syndrome Treatment Market

Market Overview

The global "marfan syndrome treatment market"size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2022-2029).

 Marfan syndrome is an inherited disorder affecting connective tissue, consisting of fibers that support and anchor organs and other body structures. The heart, eyes, blood vessels, and skeleton are the most commonly affected organs in Marfan syndrome.

 Get Free sample :  https://www.datamintelligence.com/download-sample/marfan-syndrome-treatment-market

 Market Dynamics

There are many factors driving the market growth of Marfan syndrome treatment, one such important driver which is expected to drive the market growth is the increasing research and development.

  Increasing research and development is expected to drive the global Marfan syndrome treatment market in the forecast period

 Marfan syndrome is a genetic condition. It is caused by a mutation in the gene that controls how the body produces fibrillin. Fibrillin is a protein that is important in the connective tissue of your body. Marfan syndrome is usually inherited from one's parents. If you have Marfan syndrome, you have a 50% chance of passing the faulty gene on to your children. A spontaneous mutation causes Marfan syndrome in approximately one out of every four cases. As a result, the affected person is the first in their family to be affected by the condition. The Center for Marfan Syndrome and Related Aortic Disorders prioritizes molecular genetic research on Marfan syndrome and other inherited aortic disorders. Pioneering work in cardiovascular surgery has led to increased research and practice in all aspects of cardiac care. Clinicians and researchers at the Falk Center for Cardiovascular Research and the Donald W. Reynolds Cardiovascular Clinical Research Center are pushing the boundaries of knowledge and improving their understanding and ability to diagnose and treat Marfan syndrome and other aortic disorders.

 On August 3rd, 2021, The Marfan foundation updated its research grant program to support transformative science. The Marfan Foundation's Research Grant Program is intended to provide financial assistance to investigators working on any or all aspects of Marfan syndrome, VEDS, EDS, LDS, and other genetic aortic and vascular conditions. Grants are awarded based on proposal evaluation by The Marfan Foundation Scientific Advisory Board, with the Board of Director's approval.

 Limited scientific data and treatment availability is expected to hamper the market growth

 There is no cure for Marfan syndrome, treatment focuses on preventing the disease's various complications. Following the publication of several scientific research publications showing an increased risk of aortic aneurysm and dissections when using this type of antibiotic in Marfan Syndrome patients and related disorders. On December 20, 2018, the FDA issued a warning regarding the use of fluoroquinolones antibiotics in Marfan patients.

 The EMA (European Medicine Agency) previously reported other side effects of this particular antibiotic, but the risk of the aortic aneurysm has yet to be added to this list. Several national health organizations have already revised their guidelines.

 COVID-19 Impact Analysis

Pharmaceutical and biotech companies, along with governments worldwide, are collaborating to address the COVID-19 outbreak, from vaccine development to planning for medicine supply chain challenges. Approximately 115 vaccine candidates and 155 molecules are currently in the R&D pipeline. Furthermore, commonly used drugs such as hydroxychloroquine have seen a dramatic increase in demand for COVID-19 management. Because of the high demand for these drugs, manufacturers of COVID-19 management drugs have a lot of opportunities, as many developed countries are running out of them. As a result, the pharmaceutical and biotechnology industries are expected to grow significantly. This in turn is expected to drive the global marfan syndrome treatment market.

 Segment Analysis

Aortic dilation segment is expected to dominate the global marfan syndrome treatment market

 The aorta can be weakened by Marfan syndrome. The heart pumps more blood than usual during pregnancy. This can put additional strain on the aorta, increasing the risk of a fatal dissection or rupture. The goal of Marfan syndrome surgery is to prevent aortic dissection or rupture and to treat valve problems. Surgery is recommended if the aorta diameter is greater than 4.7 cm (centimeters) to 5.0 cm (depending on the patient's height) or if the aorta is enlarging rapidly.  A cardiologist may also compute the aortic root diameter to height ratio, as this may influence whether or not you should have surgery. During surgery, the dilated aorta is replaced with a graft. Valve repair or replacement surgery is required if Marfan syndrome causes a leaky aortic or mitral valve (regurgitation), changes in the left ventricle (left lower chamber of the heart), or heart failure.

 In MFS, surgical treatment of the dilated or dissected aortic root has also evolved over the last 30 years. The composite graft, which consisted of a prosthetic valve fixed in a vascular conduit to which the coronary arteries were anastomosed, was the first significant advancement. The continued excellent results in many reports around the world have resulted in a progressive reduction in the aortic root diameter at which prophylactic repair is advised.

 Global Marfan Syndrome Treatment Market- Geographical Analysis

 North America region accounted for the largest market share in the global marfan syndrome treatment market

 The increasing incidence of marfan syndrome in North America region and the improving healthcare are expected the drive the market in this region.

 Marfan syndrome affects approximately 50,000 people in the United States (or three out of every 5,000 people). Marfan syndrome affects both men and women. It occurs in one out of every 20,000 live births.

 On November 29, 2020, Unichem Laboratories received ANDA approval from the United States Food and Drug Administration (USFDA) for its Atenolol and Chlorthalidone Tablets,  50 mg/25 mg and 100 mg/25 mg to market a generic version of Alvogen Malta Operations' TENORETIC (atenolol and chlorthalidone) Tablets. They are prescribed to treat hypertension and lower blood pressure which is one of the side effects of Marfan syndrome.

View Full Report : https://www.datamintelligence.com/research-report/marfan-syndrome-treatment-market

 Competitive Landscape

The global Marfan syndrome treatment market is moderately competitive with limited drug approvals, company acquisitions, and mergers.

 Some of the major key players in this market are Zydus Cadila Healthcare Ltd., Aurobindo Pharma USA, Teva Pharmaceuticals, Merck, Lupin Pharmaceuticals, Inc., AdvaCare Pharma, Tianyu Pharmaceutical Co., Ltd., Truman Healthcare, and Sun Pharmaceutical Industries Ltd..  

 Enquiry Before Buying :  https://www.datamintelligence.com/enquiry/marfan-syndrome-treatment-market

[pharmaworldtoday]

FDA warns of increased risk of ruptures or tears in the aorta with fluoroquinolone antibiotics in certain patients FDA Drug Safety and Availability (12/20/2018) FDA cautioned Thursday that fluoroquinolone antibiotics may increase the risk of rare but serious events of ruptures or tears in the aorta. The tears, known as aortic dissections, or ruptures of an aortic aneurysm, can lead to serious bleeding or even death. According to FDA, "Fluoroquinolones should not be used in patients at increased risk unless there are no other treatment options available. People at increased risk include those with a history of blockages or aneurysms (abnormal bulges) of the aorta or other blood vessels, high blood pressure, certain genetic disorders that involve blood vessel changes, and the elderly." A new warning about this risk must be added to the prescribing information and patient Medication Guide for all fluoroquinolones, FDA said. The agency's warning is based on cases reported to FDA and four published observational studies that indicated a higher risk of aortic aneurysm or dissection associated with fluoroquinolone use. The underlying mechanism for this risk is not known, and the background risk of aortic aneurysm can vary depending on the population. The background risk has been estimated from nine aortic aneurysm events per 100,000 people per year in the general population to 300 aortic aneurysm events per 100,000 people per year in individuals at highest risk. Because multiple studies showed higher rates of about twice the risk of aortic aneurysm rupture and dissection in those taking fluoroquinolones, FDA determined the warnings were warranted to alert health care professionals and patients. #pharmacytimes #pharmanews #alert #fda #PharmaWorldToday #pharmacyschool #pharmacist #pharmacy #pharmacology #drugs #medicine #medicines #medicinestudent #medstudent #nursingstudent #medstudents #pharmacyrocks #pharmacytech #pharmd #pharmacylife #medical #health #facts #gpatexam #niper #usmle https://t.co/lHNPZco7x2 https://www.instagram.com/p/BrsSA_NB2xf/?utm_source=ig_tumblr_share&igshid=v9vvewoidbf2

[lindamcsherry]

Side Effects of Avelox, Other Antibiotics Still Not Well Understood

Drug manufacturers, doctors and scientists still do not know why the side effects of Avelox, Levaquin, Cipro and similar antibiotics cause a form of permanent nerve damage known as peripheral neuropathy; and a new study suggests that may be because they aren’t trying very hard. 

A report published recently in the scientific journal Nature explains how there has been very little effort to examine the side effects of the class of antibiotics known as fluoroquinolones, despite decades of concerns and tens of thousands of adverse event reports filed with the FDA. The lack of investigation comes from a reticence to look at drugs that have already been on the market for years, as well as a very real fear of being blacklisted and discredited by pharmaceutical companies, according to the report.

In August 2013, the FDA required the makers of all fluoroquinolones to provide stronger warnings about the peripheral neuropathy risk from the antibiotics, indicating problems may last for months or years after an individual stops taking the drug. The new label now warns patients to contact their doctors and consider switching to a different class of antibiotics if they experience symptoms of peripheral neuropathy.

The widely used class of antibiotics has been on the market since the 1980s, and the report indicates that there’s been relatively little interest in actually investigating if the drugs may have widespread health problems.

One potential problem that is under-researched is the risk of mitochondrial damage. Mitochondria provides power to the cells in our body, and if a drug causes mitochondrial toxicity it could theoretically impact every system in the human body, resulting in a wide array of health effects, including things like peripheral nerve damage.

But research needs funding, and going back to look at old drugs isn’t a top priority for federal agencies or universities with limited research funding streams. In addition, drug companies have blacklisted doctors in the past for conducting research that showed their drugs were linked to adverse health effects, or which got their drugs recalled.

In some cases, the companies went as far as purposefully discrediting doctors and destroying their careers, the report notes. These factors make it hard for researchers to afford or justify such research.

The FDA issued a major fluoroquinolone antibiotics warning in May 2016, due to a variety of “disabling and potentially serious side effects,” which led the agency to conclude that the risks may outweigh the benefits associated with using the medications to treat uncomplicated infections.

That warning concerned reports of permanent nerve damage, known as peripheral neuropathy, as well as tendon ruptures and other health risks.

Concerns about the risk of aortic dissection and aortic aneurysm with fluoroquinolones emerged in late 2015, following the publication of a report in the medical journal JAMA Internal Medicine, which found that current use of Levaquin, Avelox or other similar antibiotics was associated with a two-fold increased risk of suffering an aortic aneurysm or dissection injury.

Hundreds of Avelox lawsuits, Levaquin lawsuits and Cipro lawsuits have been filed in recent years, each raising similar allegations that the drug makers failed to adequately investigate the safety of their drugs or warn about the disabling side effects. Plaintiffs maintain that they may have avoided long-term and permanent peripheral neuropathy problems if adequate warnings had been provided.

The post Side Effects of Avelox, Other Antibiotics Still Not Well Understood appeared first on AboutLawsuits.com.